In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS. Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept. Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses. The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing. Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS. The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024. The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs. In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M. An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS. More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said. The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile. Dr. Atrash reviews real-world data on four selinexor-based triplets used in the treatment of relapsed or refractory myeloma. At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia. Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial. Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment. Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases. The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent. A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment. Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma. Stefan K. Barta, MD, MS, discusses his recent study on central nervous system relapse in T-cell lymphomas.